natgillin/translations-raw huggingface dataset:
calculating an amount of resources for the ACK or NACK based on the resource allocation information, wherein the calculated amount of the resources does not exceed a maximum amount of resources; and 
Uređaj bazne stanice (100) prema zahtjevu 8, naznačen time da se količina resursa za ACK ili NACK koji se istovremeno odašilju sa odlaznim podacima izračunava tako da količina resursa ne prelazi unaprijed određenu količinu.
The method of claim 47, wherein said synthetic substance has a density, at an end of the chemical reaction for expansion and setting, in fully confined conditions, of 1200 kg/m3. 
Postupak prema jednom ili više prethodnih zahtjeva, naznačen time, da spomenuta sintetička tvar (4), na kraju kemijske reakcije proširenja i postavljanja, u potpuno ograničenim uvjetima, ima gustoću uglavnom 1200 kg/m'.
Among the clinical parameters, dystrophy, onycholysis, onychoschizia and ungual brittleness have been measured by a 4-point semi quantitative scale. 
Od kliničkih parametara, distrofija, oniholiza, listanje noktiju i ungualna lomljivost mjereni su pomoću semikvantitativne skale od 4 točke.
The necessity, which is essential to the teaching of the invention, of protecting the groove structures 4 during mechanical machining exists irrespectively of how or where these groove structures 4 are formed in the plate-shaped composite structure. 
Nužnost koja je bitna za smisao izuma, naime zaštita brazdastih struktura 4 tijekom mehaničke strojne obrade, postoji bez obzira kako ili gdje su te brazdaste strukture 4 oblikovane u pločastoj kompozitnoj strukturi.
The pharmaceutical composition according to claim 1, wherein rosuvastatin calcium is present in the core in a proportion of 2 - 20%, particularly 3.467 - 13.867%. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je rosuvastatin-kalcij prisutan u jezgri u udijelu od 2-20%, osobito 3,467-13,867%.
A compound for use according to claim 1, wherein X is Cl. 
Spoj za upotrebu prema Zahtjevu 1, pri čemu X predstavlja CI.
A compound according to claim 55, wherein R9a is selected from the group consisting of: wherein R10 is C1-C6alkyl, C3-C6cycloalkyl, amino optionally mono- or di-substituted with C1-C6alkyl, amido, heteroaryl or heterocyclyl. 
Spoj u skladu sa zahtjevom 56, naznačen time, da R9a je [image] gdje R10 je H, C1-C6alkil, C3-C6cikloalkil, amino, amido, heteroaril ili heterociklil.
The method according to claim 2, wherein said gelatinized or pregelatinized starch is selected from the group consisting of rice starch and maize starch, said starch in an amount from 15 to 40% by weight. 
lecitina, koji je lecitin E322, gdje se navedeni lecitin bira iz skupine koju čine kukuruzni, suncokretov ili sojin lecitin; i u količini je koja se kreće od 0,1 do 1,5 %, težinski.
or a pharmaceutically acceptable salt thereof, with an aldehyde under suitable conditions to form the compound of formula (6), or a pharmaceutically acceptable salt thereof. 
HR P20140486 T1 ili njegove farmaceutski prihvatljive sol, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6), ili njegove farmaceutski prihvatljive soli.
A further subject of the present invention is a method of calibrating an assay according to the present invention wherein binder, preferably an antibody, is used that binds to a region of at least amino acids within mature adrenomedullin and/or adrenomedullin-Gly amino acids 1-16 (SEQ ID No. 
Postupak kalibriranja ispitivanja u skladu s patentnim zahtjevom 17, naznačen time što se upotrebljava ligand koji se veže na područje od najmanje 5 aminokiselina unutar zrelog adrenomedulina (amida 1-52) i/ili aminokiseline 1-16 adrenomedulina-Gly (SEQ ID No.
The invention provides compounds of the formula I: 
Spoj, naznačen time, da ima formulu I:
Process according to any of the previous claims, wherein a second membrane is used to separate sulphuric acid from a stream rich in monosaccharides, which is obtained after hydrolysis of said organic matter using sulphuric acid, thus producing a weak sulphuric acid stream, after which said stream rich in monosaccharides is fed to a fermentor and said weak sulphuric acid stream is fed to an anaerobic acidification and sulphate reduction step. 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time, da se koristi druga membrana za odvajanje sumporne kiseline od toka bogatog monosaharidima, koji se dobije nakon hidrolize spomenutih organskih tvari uporabom sumporne kiseline, te time proizvodnjom toka slabe sumporne kiseline, nakon čega se spomenuti tok bogat monosaharidima ubacuje u fermentor, a spomenuti tok slabe sumporne kiseline se ubacuje u fazu anaerobne acidifikacije i sulfatne redukcije.
A pharmaceutical composition for use in treating multiple sclerosis, the composition consisting of: 
Farmaceutski pripravak za upotrebu u liječenju multiple skleroze, naznačen time da se pripravak sastoji od:
An immunogenic composition according to claim 9 wherein the first proximal end is within a short repeat and/or the second proximal end is within a short repeat. 
Imunogeni pripravak u skladu s patentnim zahtjevom 10, naznačen time što se prvi proksimalni kraj nalazi u kratkom ponavljanju i/ili drugi proksimalni kraj se nalazi u kratkom ponavljanju.
The method according to claim 3, wherein the size reducing means comprises at least one series of parallel or intersecting sheets or wires that form at least one size reducing net. 
Metoda u skladu sa patentnim zahtjevom 4, naznačena time da se sredstva (3) za smanjivanje veličine sastoje od najmanje jedne serije paralelnih ili presjecajućih ploča ili žica koje formiraju najmanje jednu mrežu za smanjivanje veličine.
A method according to any of clauses 15 to 17, in which the activator composition is contained within one or more water-soluble packages and is released from the one or more water-soluble packages as they are dissolved by the water. 
Postupak prema zahtjevu 8, naznačen time što se pripravak aktivatora nalazi unutar jednog ili više pakiranja topljivih u vodi 1 oslobađa se 12 jednog ili više pakiranja topljivih u vodi dok se otapaju u vodi.
Headset apparatus according to claim 35 in which said headwear signal conduit means is an electrically conductive element embedded directly within said body of the earshell. 
Slušalice prema zahtjevu 35, naznačene time, da je navedeni naglavni signalni vod električni provodljivi element ugrađen izravno unutar spomenutog trupa od školjke za uho.
An amino acid sequence that is directed against and/or that can specifically bind to human IL-17A, IL-17F and IL-17A/F (class 4), characterized in that the amino acid sequence binds to a L74A or a Y85A or a N88A IL-17A mutant with significantly reduced affinity as compared to binding to the wildtype IL-17A sequence. 
Polipeptid prema bilo kojem od zahtjeva 1-5, naznačen time da se druga sekvenca aminokiseline može specifično vezati na ljudski IL-17A, IL-17F i IL-17A/F, pri čemu se druga sekvenca aminokiseline veže na L74A, ifii Y85A i/ili N88A IL-17A mutant sa značajno smanjenim afinitetom u usporedbi s vezanjem na divlji tip IL-17A sekvence.
The process according to any one of claims 1 to 11, characterized in that, after step e), the precipitated calcium carbonate is upconcentrated or dried. 
Proces prema bilo kojem od zahtjeva 1 do 10, naznačen time da se nakon koraka e) taložni kalcijev karbonat koncentrira ili osuši.
A device according to claim 1, wherein the transmission ratio between the actuation force and the closing force is greatest at the open position of the lever and is smallest at the closed position of the lever during a rotational movement of the lever around its rotational axis. 
Naprava u skladu s patentnim zahtjevom 2, naznačena time što je omjer prijenosa između sile pokretanja i sile zatvaranja najveći kod otvorenog položaja poluge (21), a najmanji kod zatvorenog položaja poluge tijekom Totacijskog pomicanja poluge oko svoje osi vrtnje (L).
The composition of any preceding embodiment, wherein the composition is for use in a method of reducing IL-17 production or reducing Th17 cell differentiation in the treatment or prevention of a disease or condition mediated by IL-17 or the Th17 pathway. 
Sastav za upotrebu prema bilo kojem prethodnom zahtjevu, pri čemu je sastav za upotrebu u postupku smanjenja proizvodnje IL-17 ili smanjenja diferencijacije Th17 stanica u liječenju ili prevenciji raka.
When using a system for cell cultivation comprising an external column, the solid support is preferably located within the external column. 
Kada se rabi sustav za uzgoj stanica koji obuhvaća vanjsku kolonu, kruta potpora poželjno je locirana unutar vanjske kolone.
A pharmaceutical composition comprising the compound of any one of items 1 to 3 and a pharmaceutically acceptable excipient. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3 1 farmaceutski prihvatljivu pomoćnu tvar.
Compound 68 was obtained as a gray solid from compound 67 by method I. 
Spoj 68 se dobiva kao siva krutina iz spoja 67 pomoću postupka I.
a melting point of about 183°C. 
- talištem na oko 183*C.
contacting 4-(2-(methylsulfonyl)pyrimidin-4-yl)pyridin-2(1H)-one (VII) with a strong base in an organic solvent and subsequently adding VI to afford XI; 
(e) dovođenje u doticaj 4-(2-(metilsulfonil)pirimidin-4-iDpiridin-2(1H)-ona (VID s jakom bazom u organskom otapalu i uzastopno dodavanje VI, kako bi se dobio XI; iS
In other embodiments, the condition is an autoimmune disease, such as rheumatoid arthritis, lupus, Crohn's disease, or psoriasis. 
Farmaceutski pripravak za uporabu prema zahtjevu 43, naznačen time da je stanje reumatoidni artritis, lupus, Crohnova bolest, ili psorijaza.
The compound-linker molecule according to claim 8 having a structure represented by formula (VI-t) 
Tvar molekula poveznik u skladu s patentnim zahtjevom 8 koja ima strukturu predstavljenu formulom (VI-t):
Another embodiment, consists in a composition such as described above which comprises, moreover, as a combination product for simultaneous, separate or sequential use, an anti-tumour antibody. 
Pripravak iz patentnog zahtjeva 14, naznačen time da dalje sadrži jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest antitumorsko antitijelo.
The left atrial occlusion device according to claim 1, wherein the internal channels of the clamping jaws have straight axis of symmetry. A left atrial appendage occlusion device comprising: 
Uređaj za zatvaranje, sukladno patentnom zahtjevu 1 ili 2, naznačen time što unutarnji kanali (5) stezaljki (2) imaju ravne simetrije osi.
remainder water. Suspension concentrate according to any of the above claims 1 to 7, wherein the antifoaming agent is perfluoroalkylphosphinic acid or salt thereof. 
Koncentrat otopine u skladu s bilo kojim od prethodnih patentnih zahtjeva 1 do 7, pri čemu je sredstvo protiv pjenjenja silikonsko ulje, perfluoroalkilfosfinska kiselina ili njena sol.
After stirring for 3 minutes propyl bromide was added (14 µL, 0.15 mmol) and the resulting mixture stirred for an hour. 
Nakon miješanja tijekom 3 minute, dodan je propil bromid (14 uL, 0.15 mmol) i rezultirajuća smjesa se miješa još jedan sat.
Process (100) for preparing a water/diesel fuel emulsion according to claim 13, characterized in that the step of sending the pre-mixed mixture to a mixing device (5) for subjecting the mixture to a turbulent flow according to at least one first helical path is carried out inside a tubular duct (9) into which the pre-mixed fluid enters at a pressure p1 and from which the pre-mixed fluid comes out at a pressure p2, with p1 >p2. 
Postupak (100) za pripremanje emulzije goriva voda/dizel prema zahtjevu 13, naznačena time da se korak slanja prethodno izmiješane smjese u uređaj za miješanje (5) radi podvrgavanja smjese turbulentnom strujanju u skladu s barem jednom prvom spiralnom putanjom provodi unutar cjevastog kanala (9) u koji ulazi prethodno izmiješani fluid s lakom p1 i iz kojeg prethodno izmiješani fluid izlazi s tlakom p2, gdje je pl >p2.
For zirconia in the metastable tetragonal or cubic crystalline phase, the particle size is preferably in the range of 5-80,000 nm, such as 20-2000 nm, though it is believed that a mean particle size in the range of 50-1000 nm, such as 50-500 nm, provides the best balance between optical and structural properties. 
Za cirkonijev oksid u metastabilnoj tetragonskoj ili kubičnoj fazi, veličina čestica je preferirano u rasponu od 5-80000 nm, kao što je 20-2000 nm, mada se vjeruje da je srednja veličina čestica u rasponu od 50-1000 nm, kao što je 50-500 nm, a koji je najbolji balans između optičkih i strukturnih svojstava.
The graph below shows a representative figure from two independent assays. 
Dijagram dan niže prikazuje reprezentativnu stiku iz dva neovisna ispitivanja, i Peptid 6
positioning the fabric strip around said loading members so that the first welt protrudes above from the loading members for a length corresponding to the difference between said axial size of the loading members and said height of the fabric strip, wherein in said positioning step the fabric strip is slack; 
– stavljanja trake od tkanine (5) oko navedenih naprava za punjenje (31), tako da se prvi obrub (6) pruža odozgo, od naprava za punjenje u duljini koja odgovara razlici između navedene aksijalne veličine naprava za punjenje i navedene visine trake od tkanine, gdje je u navedenom koraku stavljanja traka od tkanine labava;
The immunogenic composition of claims 1-14, for use in the treatment or prevention of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); and/or 
Fuzijski protein, imunogeni pripravak, ili cjepivo u skladu s patentnim zahtjevima 1-19, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju akutnih egzacerbacija kronične opstruktivne plućne bolesti (AE-COPD).
The method according to claim 5, wherein the composition is in the form of an emulsifiable concentrate and that the method further comprises a preliminary step of dispersing said concentrate in water before application. 
Postupak prema bilo kojem od zahtjeva 9 ili 10, naznačen time da je pripravak u obliku emulzijskog koncentrata i da postupak nadalje prije nanošenja obuhvaća prethodni korak dispergiranja navedenog koncentrata u vodi.
The compound or a pharmacologically acceptable salt thereof, or a hydrate of the compound or pharmacologically acceptable salt thereof, according to claim 1 or 2, wherein R1 represents a methyl group, an ethyl group, a methoxyethyl group, a cyclopropyl group, or a cyclopropylmethyl group. 
Spoj ili njegova farmakološki prihvatljiva sol, ili hidrat spoja ili njegova farmakološki prihvatljiva sol, u skladu sa patentnim zahtjevom 1 ili 2, gdje R1 predstavlja metil grupu, etil grupu, metoksietil grupu, ciklopropil grupu, ili ciklopropilmetil grupu.
The hydrolysis is stopped when the concentration of the aqueous layer indicates the conversion is at 35 - 42%, generally within about 4 - 36 h, depending on the activity of the enzyme. 
Hidrolizu se prekine kada koncentracija vodenog sloja ukaže da je prevođenje provedeno 35 do 42 %, općenito unutar približno 4 do 36 sati, ovisno o aktivnosti enzima.
It is well known that some polymeric materials, for example PET, may only be used once in their original form. 
Dobro je poznato da neki polimerni materijali, na primjer PET, mogu samo jednom biti korišteni u svom originalnom obliku.
The solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. 
Spoj 1z zahtjeva 1, pri čemu je spoj: ili njegova farmaceutski prihvatljiva sol.
The process of claim 1 or 2, wherein in step (c) the amount of 14-hydroxycodeinone in the oxycodone salt composition is lowered by removing 14-hydroxycodeinone from the oxycodone salt composition formed in step (b). 
Postupak prema bilo kojem zahtjevu od 1 do 4, naznačen time da je sastav oksikodon hidroklorida koji ima razinu 14-hidroksikodeinona manju od 25 ppm naknadno hidrogeniran kako bi se dodatno smanjila količina 14-hidroksikodeinona.
Anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment binding to adrenomedullin or anti-ADM non-Ig scaffold binding to adrenomedullin for use in therapy of an acute disease or acute condition of a patient according to any of claims 1 to 5, wherein said antibody or fragment or scaffold is not ADM-binding-Protein-1, complement factor H. 
Protutijelo protiv adrenomedđulina (ADM) ili fragment protutijela protiv ADM koji se veže na adrenomedulin ili okosnica ne-Ig protiv ADM koja se veže na adrenomedulin, namijenjeni upotrebi u terapiji akutne bolesti ili akutnog stanja kod pacijenta u skladu bilo kojim od patentnih zahtjeva 1 do 5, naznačeni time što navedeno protutijelo ili fragment ili okosnica nisu Protein-1 koji se veže na ADM, komplementni čimbenik H.
The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein b is 1. 
Spojevi ili sol za upotrebu prema zahtjevu 6, pri čemu b je 1.
arranging technical installations (16, S) within said cuboid shape, 
(iv) organizirajući tehničke instalacije (16, S) unutar navedenog kuboidnog oblika,
wherein m is 1, 2, or 3, RF is H or C1-3alkyl, and RE is H, C1-3alkyl, or SO2CH3, and wherein each of the foregoing pyridyl, pyrrolidinyl, piperidinyl, and piperazinyl groups is optionally substituted at one or more carbon atoms with 1, 2, or 3 independent occurrences of R11, and at one or more substitutable nitrogen atoms with R12; 
LONH gdje je m jednak 1, 2 ili 3, R* jeHili C,galkil,1 R? je H, Ci3 alkil ili SOLoCH., i gdje je svaka od prethodno navedenih piridil, pirolidinil, piperidinil i piperazinil grupa izborno supstituirana na jednom ili više atoma ugljika sa 1, 2ili 3 nezavisna R'!, i na jednom ili više atoma dušika, koji se mogu supstituirati, sa R'?,
The means for agitating 108 the container contents can be a blade element coupled to an impeller in a shaft or other transmission means. 
Dio za miješanje 108 sadržaja posude može biti oštrica spojena na propeler na osovini ili na drugo sredstvo prijenosa.
The fatty acid derivative may also be used to adjust the mechanical properties of the coating i.e. 
Derivat masne kiseline se također može upotrijebiti i za podešavanje mehaničkih svojstava prevlake, tj.
In some embodiments, the nucleic acid encoding the amino acid sequence of SEQ ID NO:47 is the nucleic acid sequence of SEQ ID NO:34. 
Postupak prema patentnom zahtjevu 7, naznačen time, da je nukleinska kiselina koja kodira anti- VEGE protutijelo ili fragment anti-VEGF protutijela odabrana iz skupine koju čine nukleinskokiselinska sekvenca ID BR.
an internal abutment part 36 in the second collar 35 for closing the outlet end of the dispensing valve 30. 
- - unutarnji dosjedni dio 36 u drugom prstenu 35 za zatvaranje izlaznog kraja ventila za točenje 30.
Wind system (1) according to claim 2, characterised in that said spring is compressed due to said tension of said rope (4). 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da su spomenuta kolica (11) opremljena kotačima (16, 17) da bi nosili težinu spomenutih kolica (11).
The medicament may comprise any one of the embodiments of formula I described above. 
Takav lijek može sadržavati bilo koju verziju gore opisane formule I.
at least about 10 ppm silver, preferably at least about 20 ppm silver, more preferably at least about 25 ppm silver; and/or 
najmanje 10 ppm srebra ili najmanje 20 ppm srebra ili najmanje 25 ppm srebra; i/ili
adding additional p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate to the mixed solution under cooling, wherein the additional p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate is added in such an amount that the total molar equivalent thereof with the p-toluenesulfonic acid or p-toluenesulfonic acid monohydrate of step (a) is 1 molar equivalent or more with respect to the compound represented by formula (B) of step (a); and 
(b) dodavanje dodatne p-toluensulfonske kiseline ili monohidrata p-toluensulfonske kiseline u pomiješanu otopinu uz hlađenje, pri čemu dodatna p-toluensulfonska kiselina ili monohidrat p-toluensulfonske kiseline se dodaje u takvoj količini da je njezin ili njegov ukupni molarni ekvivalent u odnosu na p-toluensulfonsku kiselinu ili monohidrat p-toluensulfonske kiseline iz koraka (a) jednak 1 molarni ekvivalent ili više s obzirom na spoj predstavljen formulom (B) iz koraka (a); i
The compound of claim 8, wherein R5 is C3-C6 alkyl or CH2-C3-C6-cycloalkyl and where R5 is optionally substituted with halogen, hydroxy, or methoxy. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time, da je R5 C3-C6 alkil ili CH2-C3-C6-cikloalkil, a pri čemu je R5 po izboru supstituiran s halogenenom, hidroksi ili metoksi.
is H. The compound according to claim 1 wherein R2 is in a position. 
Tvar u skladu s patentnim zahtjevom 1 pri čemu je R2 u a položaju.
the variable light chain sequence of SEQ ID NO: 95 and variable heavy chain sequence of SEQ ID NO: 109. 
(b) sekvencu jakog lanca od SEQ ID NO: 147, i sekvencu slabog lanca od SEQ ID NO: 142;
The transmitter of claim 1 or 2, wherein the block is evenly divided into the four sub-blocks when a value of the L1 TI mode information corresponds to '10' and wherein the block is evenly divided into the eight sub-blocks when the value of the L1 TI mode information corresponds to `11'. 
Prijenosnik iz patentnog zahtjeva 1 ili 2, pri čemu je blok jednoliko podijeljen u četiri podbloka kada vrijednost informacije vrste L1 TI odgovara '10' i pri čemu je blok jednoliko podijeljen u osam podblokova kada vrijednost informacije vrste L1 TI odgovara '11'.
Example A: Formulation of the invention. 
Broj objave europskog patenta:
a light chain variable region comprising a light chain complementarity determining region (CDR)1 comprising the amino acid sequence of SEQ ID NO: 9, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and 
Upotreba monoklonskog protutijela, ili njegovog funkcionalnog dijela, koje prepoznaje 1 veže se na B-amiloidni protein, te sadrži CDRI1 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9% CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11;
Proper treatment prolongs lifespan of wood, what results in cheaper maintenance and safety of wooden construction. 
Odgovarajuća obrada produžava životni vijek drva, što rezultira jeftinijim održavanjem i sigurnošću drvene konstrukcije.
A composition comprising the protein scaffold of any one of claims 1-4 and at least one pharmaceutically acceptable carrier or diluent, optionally further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a functional food active, a cytokine, and a cytokine antagonist. 
Sastav koja sadrži platformski protein prema bilo kojem od patentnih zahtjeva od 1 do 4 i najmanje jedan farmaceutski prihvatljivi nosač ili otapalo, opcionalno dalje sadrži najmanje jedan spoj ili polipeptid izabran iz detektabilnih etiketa ili reportera, TNF antagonista, anti-infektivnog lijeka, lijeka kardiovaskularnog (CV) sustava, lijeka centralnog nervnog sustava (CNS), lijeka autonomnog nervnog sustava (ANS), lijeka respiratornog trakta, lijeka gastrointestinalnog trakta(GI), hormonalnog lijeka, lijeka za tekuću ili elektrolitnu ravnotežu, hematološkog lijeka, antineoplastika, imunomodularnog lijeka, oftalmološkog, ušnog ili nazalnog lijeka, topičkog lijeka, funkcionalne aktivne hrane, citokina, i citokin antagonista.